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Result: The human pancreas cDNA library was constructed
successfully. The reconstructed bait plasmid (pGBKT7-HCV
NS4B) was transformed into yeast cells AHl09 successfully.
Eight proteins interacting with HCV NS4B were found.
Conclusion: Some of the eight pancreatic proteins may be
related with metabolisms of glucose and lipid.
PP-135 The efﬁciency of blood-borne HCV ampliﬁcation
in different three dimensional cell culture
systems in vitro
Y. Qi1, Q.L. Jin1, X.Y. Wen1, J.Q. Niu1. 1Division of liver
diseases, the ﬁrst hospital of Jilin University, Changchun,
China
Background: Immortalized human hepatocytes HuS-E/2
cells cultured in Hollow ﬁber (HF) support the blood-borne
hepatitis C virus (HCVbb) infection in vitro. But several
limits of the HF system stand in the way of its usage
for HCV research. This study is to evaluate the efﬁciency of
different three dimensional (3-D) culture systems for HCVbb
ampliﬁcation in vitro.
Methods: HuS-E/2 cells were cultured in different 3-D cell
culture systems, HF, hydrocell plate (HP) and mebiol gel
(MG). Serum and plasma from hepatitis C patients were used
for infection of the cells. Plasma was pre-treated with Ca2+
containing solution for the infection. Cell proliferation was
monitored with XTT assay. HCV ampliﬁcation in 3-D cultured
cells was measured with real time PCR.
Results: Stable cell proliferation was observed in both
HF and MG system. HCVbb ampliﬁcation in HuS-E/2 cells
which were cultured in HF, HP and MG exhibited the similar
patterns although the titer in cells of different systems is
variational.
Conclusion: All three 3-D systems can support the
proliferation of HCVbb. The selection of the system for
research depends on other factors such as the objective of
the research, culture condition and so on.
PP-136 Antiviral therapy of patients with
decompensated cirrhosis associated with
hepatitis C virus infection
F.P. Ji1 *, H. Deng1. 1Department of Infectious Disease,
the Second Afﬁliated Hospital, College of Medicine, Xi’an
Jiaotong University, China
Patients with hepatitis C virus (HCV)-related decompensated
cirrhosis are associated with a poor prognosis. Although
liver transplantation (LT) offers an effective treatment,
HCV reinfection of the transplanted graft is a critical
and almost inevitable complication with major inﬂuence
on graft- and patient survival. Antiviral therapy of this
patient population is difﬁcult, the use of interferon and
ribavirin might expose these patients to severe treated-
related side effects as a large proportion of them have
pre-existing hematological cytopenias. However, antiviral
treatment in patients with advanced liver cirrhosis is
a potential option for two reasons: ﬁrst, clearing or
suppressing HCV before LT may reduce or eliminate the
risk of recurrent hepatitis C in the transplanted liver and
thereby improve survival; second, clearing HCV in cirrhotic
patient may halt disease progression and avoid the need
for transplantation. Basd on AASLD and ESAL guidelines,
antiviral therapy in this patient population is generally
recommended, but indication, optimal timing, dose and
duration of therapy are not clearly deﬁned. In this article,
the results obtained by antiviral regimens administered to
HCV-related decompensated cirrhosis are discussed.
PP-137 Suppression of HCV replication in hepatocytes
through a selective induction of IRF7
Q.L. Jin1 *, X.Y. Wen1, C. Yang1, J.Q. Niu1. 1Department
of Hepatology, First Hospital, Jilin University, Changchun,
China
Background: A high risk of chronicity is the major concern
of HCV infection and chronic infection often leads to liver
cirrhosis and hepatocellular carcinoma. Although proportion
of patients achieving a sustained virological response has
been increased by the introduction of combination therapy
of pegylated-IFN-alpha and ribavirin, still half of the
patients exhibits no response to the therapy. One of the
mechanisms for the establishment of persistent infection
of HCV is the escape from the host immune system.
To eliminate HCV from the hepatocytes of the patients
without possible cytotoxity due to anover induction of host
immunity, we generated a therapeutic construct, cMR3, by
which type I IFN is selectively induced in HCV infected
cells.
Methods: The cMR3 is composed of the N-terminal part
of the interferon regulatoryfactor 7 (IRF7) possessing a
dominant active function, the sequences speciﬁcally cleaved
by HCV NS3/4A protease and an ER anchor, and exhibits
apotent IFN inducing activity in HCV infected cells. After
cleavage by the HCV protease, the processed cMR3 migrates
into the nucleus and activates various IFN promoters
including IFN-alpha6, IFNbeta, and IFN stimulated response
element.
Results: The speciﬁc activation ofthe IFN promoters was
observed in both HCV replicon cells and JFH1 virus infected
cells upon introduction of the cMR3 but not in cells infected
with JEVor DENV. Expression of viral protein and viral RNA
replication were also impaired by the introduction of cMR3
into the HCV replicon cells.
Conclusion: These results suggest that the selective
expression of type I IFN in the hepatocytes infected with
HCV by the introduction of the cMR3 might be feasibleto
eliminate HCV from the chronic hepatitis C patients without
liver damage.
PP-138 CD44v6 expression in HCV-infected cells and
the correlation with apoptosis resistance
X.Y. Wen1 *, Q.L. Jin1, Y. Qi1, C. Yang1, J.Q. Niu1.
1Department of Hepatology, First Hospital, Jilin University,
Changchun, China
Background: Hepatitis C virus (HCV) infects about 170
million people worldwide and is a major cause of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
Several mechanisms have been proposed for the incidence
of HCC, including apoptosis resistance. CD44, an integral
cell membrane glycoprotein and adhesion molecule, plays
a critical role in a number of important cellular function
including activating anti-apoptosis signal pathway. The aim
of this study were to investigate the expression of CD44v6
in liver cancer tissues and to determine its correlation
with apoptosis resistance via upregulated activity of the
PI3K/AKT pathway.
Methods: We examined the expression of CD44 in liver
cancer tissues in patients with HCV-related HCC compared
with in liver tissues in health controls by Western blot and
the expression of CD44v6 in HCV replicon and JFH1-infected
cells compared with in Huh7 by FACS. Furthermore, we
investigated the apoptosis of CD44 knockdown HCV replicon
and HCV-infected cells treated by ActD compared with that
in negative control cells.
Results: HCV-related HCC liver cancer tissues expressed
signiﬁcantly higher CD44 protein levels than tissues in health
controls. Signiﬁcantly higher CD44v6 were observed in HCV
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replicon cells. Apoptosis resistance was showed in CD44
knockdown HCV replicon and HCV-infected cells treated by
ActD.
Conclusion: These results suggested that there had an
intentive relationship between CD44, especially CD44v6
expression and anti-apoptosis in liver cancer tissues.
PP-139 Cutaneous necrosis after injection of interferon
alfa-2b in a patient with HCV-related
decompensated cirrhosis
Z.X. Li1, F.P. Ji2, Z.H. Peng1, H. Deng2. 1Department
of Dermatology and Venereology, the Second Afﬁliated
Hospital, College of Medicine, Xi’an Jiaotong University,
Xi’an, China, 2Department of Infectious Disease, the
Second Afﬁliated Hospital, College of Medicine, Xi’an
Jiaotong University, Xi’an, China
Introduction: Cutaneous necrosis as a result of interferon
alfa is an infrequent complication with unknown
pathogenesis. We report a patient who developed local
cutaneous reactions at sites of injection after the
administration of interferon alfa-2b.
Case description: A 55-year-old woman with HCV-related
decompensated cirrhosis treated with every other day
subcutaneous injections of interferon alfa-2b (210MU) in
combination with ribavirin (800mg/d). Six months later,
a painful, erythematous, indurated plaque with centrally
ulcerated about 1.2 cm in diameter initially developed
on right abdomen. One week later, an additional ulcer
measuring 2 cm in maximum diameter, with peripheral
erythema and purulent contents, developed at the other
injection site on the left abdomen (Fig. 1). Results of skin
cultures were negative. A skin biopsy specimen showed
the presence of ulceration with ﬁbroplasia and vascular
proliferation consistent with a re-epithelializing ulceration.
The patient was advised to avoid injection on abdomen and
to intramuscular injection at triangular muscle with same
dose. The ulcers were treated with Mupirocin ointment,
healed in 1 months, and did not recur. Our case suggests
that the cutaneous lesions maybe healed without requiring
interruption or dose modiﬁcation of interferon after local
care and change of injection site.
Figure 1.
PP-140 Difference in liver function tests in patients
with chronic HCV-infection depend on some
predisposing factors
N. Sargsyants1 *. 1Armenicum Clinical Center, Armenia
Background: Aim of the study was comparison of liver
function tests, including ferritin, in patients with chronic
HCV-infection depends on patients age, gender, body mass
index (BMI), disease limitation, presence of anti bodies to
HBV, alcohol and drug abuse.
Methods: Evaluation of albumin, billirubin, ALT, AST, and
GGT was performed in 50 patients with chronic HCV-
infection by biochemical analyzer HumaStar 300. For
measurement of plasma ferritin level we used two-site
immunoenzymatic (“sandwich”) assay. Statistic analyses
were carried out with SPSS 11.0 and Excel.
Result: Level of AST was signiﬁcantly higher in HCV-infected
patients with obesity (BMI less than 25 56.8±8.0; BMI
25 30 59.3±11.9; BMI more than 30 79.4±20.1). GGT
was signiﬁcantly higher in HCV-infection with duration of
disease more than 10 years (less than 5 years 77.0±25.7;
5 10 years 88.7±9.7; more than 10 159.2±33.6).
Ferritinemia was higher in male in comparison with female
(326±38.4 vs. 108.2±44.7) and in long history of HCV-
infection (up to 5 years 198.8±45.9; 5 10 years
251.1±39.1; more than 10 546.5±80.8).
Conclusion: Signiﬁcant difference revealed in some liver
enzymes and ferritin depends on HCV-infected patients’
gender, BMI and limitation of disease.
Table 1. Liver function tests in patients with chronic HCV-infection
(n = 50)
Parameter Normal
range
Unit m SD SE Median Min Max 95% CI
Albumin 38 51 g/l 46.7 4.98 0.75 47 35 57.9 45.2 48.2
Bilirubin total <18.8 mmol/l 12.55 7.21 1.02 10.7 3.7 39.5 10.6 14.6
Bilirubin direct <4.3 mmol/l 3.09 2.36 0.33 2.4 0.6 12 2.44 3.75
AST <37 U/l 60.98 46.7 6.61 48 14 250 48.0 73.9
ALT <42 U/l 103.22 63.38 8.96 93 13 330 85.7 120.8
GGT 11 61 U/l 91.19 73.11 10.6 69.5 16 350 70.5 111.9
Ferritin 23.9 336.2 ng/dl 236.8 71.25 32.6 197.9 4.7 829.1 173.2 300.4
Table 2. Liver function tests in patients with chronic HCV-infection
depend on gender, age, disease limitation, BMI, HBV past-infection,
alcohol and drugs abuse
Criteria n Albumin Bilirubin ALT AST GGT Ferritin
Gender
Male
Female
42
8
46.6±0.7
45.9±1.6
12.8±1.2
12.0±1.4
110.6±9.8
75.5±24.2
65.2±8.0
54.5±14.1
104.7±12.0
59.5±26.5
326.0±38.4*
108.2±44.7
Age
<30
<31 40
41 50
>50
13
18
16
3
48.0±1.4
45.1±0.9
47.1±1.7
43.0±4.2
12.5±2.4
12.8±1.5
12.1±2.0
13.3±2.0
92.2±14.8
115.9±18.3
96.7±12.9
109.3±49.0
45.6±8.0
75.6±15.4*
53.8±7.0
78.0±26.6
76.7±14.1
96.8±20.1
99.6±20.9
71.0±8.0
157.3±32.1
357.4±50.9
293.7±90.7
90.6±18.6
BMI
<25
25 30
>30
21
21
8
47.1±1.2
45.7±1.2
48.1±1.8
14.4±2.0
10.4±1.0
13.5±2.0
106.0±15.9
90.0±13.3
117.9±15.5
56.8±8.0
59.3±11.9
79.4±20.1*
84.0±17.8
92.4±16.7
151.5±24.3
232.7±14.5
335.9±63.3
300.6±73.9
Disease limitation, years
<5
5 10
>10
13
26
10
48.2±1.4
45.4±0.7
47.6±2.2
13.0±2.6
12.8±1.5
12.4±0.7
78.2±11.2
113.6±14.0
126.8±19.7
41.3±7.2
70.4±11.0
77.5±16.6
77.0±25.7
88.7±9.7
159.2±33.6*
198.8±45.9
251.1±39.1
546.5±80.8*
HBcAb
Yes
No
16
32
46.5±1.3
46.1±0.8
9.6±0.9
14.4±1.5*
94.3±11.5
113.3±12.8
56.1±10.2
68.1±9.8
86.7±13.2
100.6±15.5
249.4±49.2
313.3±49.3
IVDU
Yes
No
23
26
46.1±0.9
46.7±1.0
12.3±1.8
13.2±1.2
109.4±13.6
104.6±12.6
54.9±7.2
72.3±11.9
85.3±11.0
110.1±18.5
326.2±47.6
262.2±52.2
Alcohol abuse
Ectb
HeT
17
32
45.0±1.0
47.2±0.9
10.4±1.1
14.1±1.5
107.7±11.6
106.4±12.7
57.0±7.3
67.9±10.3
107.2±16.4
94.1±15.1
340.2±71.7
264.8±40.5
Values are mean±SE.
*p-value <0.05.
PP-141 Study of the serodynamics and viral clearance
with Reiferon Retard® in chronic Hepatitis C
patients in Egypt
M.A. Hamid1,2 *. 1VHRL Egypt, 2Menia University, Egypt
Objective: Study Serodynamics and viral clearance with
Reiferon Retard® in naïve Egyptian HCV patients mostly
genotype 4.
Methodology: 28 HCV patients randomly selected from
78 patients treated with Reiferon Retard®. 14 showed
sustained viral response and 14 were non responders and
relapsers. Assessment of serodynamics, viral load, viral
clearance and genotyping were performed on blood samples
collected at time of recruitment and at weeks 8, 12 and
